top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable
Dec 1, 2016
Anavex Life Sciences Appoints Three Distinguished Researchers to Scientific Advisory Board
Nov 28, 2016
CTAD 2016 — Clinical Trials on Alzheimer's Disease
Nov 22, 2016
Anavex Life Sciences Announces Data on 41Week Treatment of ANAVEX 2-73 for Patients with Alzheimer's
Nov 22, 2016
Maxim Group LLC — Central Nervous System Disease Conference
Nov 14, 2016
Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic
Nov 14, 2016
Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer's
Nov 11, 2016
Investigating the Potential Neurorestorative Effects of a Clinical Sigma-1 Receptor Agonist
Nov 11, 2016
Global Mizuho Investor Conference (MIC)
Nov 11, 2016
Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic
Nov 11, 2016
Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency
Oct 4, 2016
27
28
29
30
31
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
